TRVI
Trevi Therapeutics Breaks Ground on Phase III Trials for Haduvio, Accelerating its Journey to Approval
Trevi Therapeutics has made significant strides in its development program for Haduvio, a treatment aimed at addressing idiopathic pulmonary fibrosis (IPF)-related chronic cough. According to the company's recent Q4 2025 earnings conference call transcript, Trevi secured a clear path forward for registration trials following a positive end-of-phase